The effect of sunitinib treatment was evaluated by DCE-MRI, intravital microscopy, and immunohistochemistry in pancreatic ductal adenocarcinoma (PDAC) xenografts growing in dorsal window chambers or intramuscularly in the hind leg of mice. Sunitinib selectively removed small-diameter vessels and increased blood flow velocity. The increased blood flow velocity was not sufficient to compensate for the loss of tumor vessels, and, consequently, sunitinib-treated PDAC xenografts showed increased fractions of hypoxic tissue. Ktrans derived by pharmacokinetic analysis of DCE-MRI data was sensitive to microvascular density and hypoxia in both untreated and sunitinib-treated PDAC xenografts.
This abstract and the presentation materials are available to members only; a login is required.